Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023
|
|
|
- Madeleine Greer
- 6 years ago
- Views:
Transcription
1 Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023 Table of Contents Cancer Immunotherapy Artificial Intelligence: Executive Summary The study is designed to give a comprehensive overview of the Cancer Immunotherapy Using Artificial Intelligence market segment. Research represents a selection from the mountains of data available of the most relevant and cogent market materials, with selections made by the most senior analysts. Commentary on every aspect of the market from independent analysts creates an independent perspective in the evaluation of the market. In this manner the study presents a comprehensive overview of what is going on in this market, assisting managers with designing market strategies likely to succeed. Abstract: Artificial Intelligence Applied to Cancer Immunotherapy Vastly Improves Treatments and Outcomes 1 Cancer Immunotherapy Artificial Intelligence (AI) Executive Summary 11 Cancer Immunotherapy Artificial Intelligence (AI) Market Driving Forces 11 Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces 14 Artificial Intelligence Oncology Treatment Market Shares: 16 Cancer Immunotherapy Artificial Intelligence for Hospitals Market Forecasts: Cancer Immunotherapy Artificial Intelligence Market Description and Market Dynamics: Artificial Intelligence Very Big Breakthrough in Cancer Immunotherapy Ability of AI Solutions To Discover Schemas in Large Databases Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces 25 TOC-1
2 2.1 Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces Artificial Intelligence Oncology Treatment Market Shares: Cancer Immunotherapy Artificial Intelligence for Hospitals Market Forecasts: Worldwide Checkpoint Inhibitor and Oncology Treatment Market Forecasts Cancer Statistics Cancer Among The Leading Causes Of Death Worldwide Hospital Artificial Intelligence (AI) Challenges Hospital Artificial Intelligence Software Prices: Hospital Artificial Intelligence Regional Segments: Cancer Immunotherapy Hospital Artificial Intelligence Products: Memorial Sloan Kettering Memorial Sloan Kettering Parker Institute CAR T Immunotherapy T-Cell Therapies from Merck and Bristol-Myers Squibb Memorial Sloan Kettering Cancer Diagnostic Test, MSK-IMPACT Memorial Sloan Kettering Intensified Tumor Testing Memorial Sloan Kettering Effective Sequencing Memorial Sloan Kettering Actionable the most important cancer genetargets MD Anderson Immune Therapy MD Anderson Immune Therapy MD Anderson Personalized Therapy TNBC Cancer Trials Partners Dana Farber Immunotherapy 67 TOC-2
3 3.3.1 Advanced Melanoma Has Been The Test Case For The Study Of Immune Checkpoint-Inhibiting Therapy Partners HealthCare, IBM, and GE Healthcare IBM Watson IBM Genomic And Immunotherapy Supercomputing for Patient Management Mayo Clinic and IBM Watson Google s AI Subsidiary DeepMind is Partnering With Another UK hospital Prognos Hospital Artificial Intelligence Research and Technology: IBM AI Research Neural Representation of Sketch Drawings IBM Watson Health And Broad Institute Launch Major Research Initiative To Study Why Cancers Become Drug Resistant IBM and Quest Diagnostics Research at Google Google and Nvidia Artificial Intelligence Hospital Artificial Intelligence Companies Alphabet / Google Google Artificial Intelligence Subsidiary DeepMind Healthcare Initiative Broad Institute of MIT and Harvard Foundation Medicine 88 >120k 88 >30 88 > TOC-3
4 5.3.1 Foundation Medicine General Electric (GE) General Electric Revenue by Segment GE Healthcare and Massachusetts General Artificial Intelligence Gritstone Oncology IBM IBM Watson Health IBM Active in BWH, MGH Partnership To Advance Artificial Intelligence In Health Care IBM Watson Artificial Intelligence for Oncology IBM Watson Genomics by Quest Diagnostics IBM Watson Healthcare Revenue IBM Watson Solutions Software Healthcare Revenue Juno Therapeutics Juno Therapeutics Power Of Individualized Cancer Treatment Juno Therapeutics CAR and TCR Technologies Myriad Genetics Nvidia NVIDIA Nvidia Revenue Nvidia Customer HeartFlow Medical Technology Pfizer Prognos Coding Healthcare Datasets Full Of Unstructured Text Quest Diagnostics 114 TOC-4
5 IBM Personalized Healthcare: Watson Genomics from Quest Diagnostics Quest Diagnostics Revenue Safeguard Scientifics Announces Second Quarter 2017 Financial Results Safeguard Scientifics Prognos DxCloud 117 WinterGreen Research, 118 WinterGreen Research Methodology 119 WinterGreen Research Process 120 Market Research Study 121 WinterGreen Research Global Market Intelligence Company 122 Report Description: Hospital Artificial Intelligence Models Matter 123 Abstract: Artificial Intelligence Applied to Cancer Immunotherapy Vastly Improves Treatments and Outcomes 1 Figure 1. T Lymphocycte 12 Figure 2. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces 14 Figure 3. Healthcare Safety Features Implemented by Artificial Intelligence (AI)15 Figure 4. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, Figure 5. Cancer Immunotherapy Hospital Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, Figure 6. Cancer Artificial Intelligence Components 23 Figure 7. Hospital Artificial Intelligence Predictive Functions 24 TOC-5
6 Figure 8. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces 25 Figure 9. Healthcare Safety Features Implemented by Artificial Intelligence (AI)26 Figure 10. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, Figure 11. Cancer Immunotherapy Artificial Intelligence Systems, Market Shares, Dollars, Worldwide, Figure 12. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, Figure 13. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, Figure 14. AI Replacements for Supervised Manual Techniques For Diagnosis And Care Delivery. 34 Figure 15. Hospital Artificial Intelligence Long-Term Goal 35 Figure 16. Hospital Artificial Intelligence Action Functions 37 Figure 17. Immuno-Oncology Market Applications 39 Figure 18. Key players in the immuno-oncology market 40 Figure 19. Estimated New Cancer Cases in the US in Figure 20. Trends in Cancer Incidence Rates, US, 1975 to Figure 21. Estimated Cancer Deaths in the US in Figure 22. Pancreatic Cancer Survival Rate 45 Figure 23. Trends in Cancer Death Rates Among Males, US 1930 to Figure 24. Hospital Artificial Intelligence (AI) Challenges 49 Figure 25. Hospital Artificial Intelligence (AI) Human Factors 50 Figure 26. IBM 8408 E8E PSeries AIX Power8 Server EPV4 24-Core 52 Figure 27. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, Figure 28. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, TOC-6
7 Figure 29. T Lymphocycte 55 Figure 30. MD Anderson Genetic Sequencing Services: 64 Figure 31. MD Anderson Sample quality check (DNA and RNA) 64 Figure 32. MD Anderson Cancer Immunotherapy Custom Services: 65 Figure 33. Partners Dana Farber Immunotherapy Directions 67 Figure 34. Stephen F. Hodi, MD, Director, Partners Dana Farber Melanoma Center; Director, Center for Immuno-Oncology 68 Figure 35. Truven Health Analytics Products 74 Figure 36. IBM TrueNorth Neurosynaptic System 79 Figure 37. AI Makes Words Manageable 80 Figure 38. Foundation Medicine Metrics 88 Figure 39. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Workflow 92 Figure 40. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Center of Excellence 93 Figure 41. Juno Therapeutics Immunotherapy 100 Figure 42. Chimeric Antigen Receptor (CAR) T cell Technology 101 Figure 43. T Cell Receptor (TCR) Technology 102 Figure 44. Tumor Cells Ability To Develop Resistance 103 Figure 45. NVIDIA Tesla V100 Accelerator 105 Figure 46. Nvidia Interconnect and Memory Parameters 106 Figure 47. Prognos Investors 108 Figure 48. Percent Patients with Abnormally High Test 5 years Prior to First Pancreatic Cancer Diagnosis Stratified by Test and by Year 112 Figure 49. Prognos Pancreatic Cancer Diagnosis Test Result Variance 113 Figure 50. Watson Genomics from Quest Diagnostics Features: 115 TOC-7
Table of Contents. Abstract: Hand Sanitizer 1 Hand Sanitizer Executive Summary 4
Hand Sanitizer: Market Strategies and Forecasts, Worldwide, 2018-2024 Hand Sanitizer: Executive Summary Table of Contents The study is designed to give a comprehensive overview of the Hand Sanitizer market
In Situ Hybridization: Market Strategies and Forecasts, US,
In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization
Sports Coaching Platforms: Market Shares, Strategies, and Forecasts, Worldwide,
Sports Coaching Platforms: Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021 Table of Contents Sports Coaching Platforms Executive Summary The study is designed to give a comprehensive overview
Hip and Knee Orthopedic Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide,
Hip and Knee Orthopedic Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2016-2022 Table of Contents Hip and Knee Orthopedic Surgical Robots: Executive Summary The study is designed
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology
SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology Lee M. Ellis, MD SWOG Vice Chair, Translational Medicine Departments of Surgical Oncology and
Spinal Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide,
Spinal Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2016-2022 Table of Contents Spinal Surgical Robot: Executive Summary The study is designed to give a comprehensive overview
THE ANALYTICS EDGE. Intelligence, Happiness, and Health x The Analytics Edge
THE ANALYTICS EDGE Intelligence, Happiness, and Health 15.071x The Analytics Edge Data is Powerful and Everywhere 2.7 Zettabytes of electronic data exist in the world today 2,700,000,000,000,000,000,000
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
Cardiac and Lung Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide,
Cardiac and Lung Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021 Table of Contents Cardiac and Lung Surgical Robots: Executive Summary The study is designed to give a comprehensive
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Radiology Oncology Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022
Radiology Oncology Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022 Mountains of Opportunity Picture by Susan Eustis WinterGreen Research, Inc. Lexington, Massachusetts
Equity markets. Major advances in cancer therapeutics - update 6 26 April Investment Guidance
Equity markets Major advances in cancer therapeutics - update 6 26 April 2016 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com This investment theme recommends companies
Abdominal Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, Table of Contents
Abdominal Surgical Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021 Table of Contents Surgical Robots: Executive Summary The study is designed to give a comprehensive overview of
Orthopedic Surgical Robots and Surgical Robotic Assist Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022
Orthopedic Surgical Robots and Surgical Robotic Assist Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022 Mountains of Opportunity Picture by Susan Eustis WinterGreen Research, Inc.
PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund December 2018 EXECUTIVE SUMMARY As a top-ranked pediatric cancer center, Dana-Farber Cancer Institute combines first-rate patient care with groundbreaking
Continuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment
Continuing the momentum to deliver improved performance Robert Cascella Chief Business Leader Diagnosis & Treatment Key takeaways Diagnosis & Treatment strategy is aligned with the Quadruple Aim Gaining
Sickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
Cancer Researchers Report Longer Survival Rates With Immunotherapy
http://nyti.ms/1jlz74z HEALTH NYT NOW Cancer Researchers Report Longer Survival Rates With Immunotherapy By ANDREW POLLACK JUNE 2, 2014 CHICAGO Drugs that unleash the body s immune system to combat tumors
Hip and Knee Orthopedic Surgical Implants: Market Shares, Strategies, and Forecasts, Worldwide,
Hip and Knee Orthopedic Surgical Implants: Market Shares, Strategies, and Forecasts, Worldwide, 2016-2022 Table of Contents Hip and Knee Orthopedic Surgical Implants: Executive Summary The study is designed
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to Oncology. Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to 2012 Oncology Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY WinterGreen Research, Inc. Lexington, Massachusetts www.wintergreenresearch.com
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Safinamide in the 8MM Parkinson s disease (PD)
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms
Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Wendy Broom, Ph.D. Keystone: Translational Systems Immunology, Snowbird February 1st 2018
Unleashing Big Data in Oncology: Making Real World Cancer Data Useful
June 18, 2015 Unleashing Big Data in Oncology: Making Real World Cancer Data Useful Bobby Green, MD MSCE Vice President, Clinical Strategy Senior Medical Director bobby@flatiron.com www.flatiron.com Funding
REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Rytary/IPX066 in the 8MM Parkinson s disease
The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program
Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program Joxel Garcia, MD, MBA Executive Director, Cancer Prevention and Control Platform Member, Moon Shots Program Leadership Team The
REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Nouriast in the 8MM Parkinson s Disease
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER
THE GLOBALIZATION OF HEALTHCARE DR. BLAIR GIFFORD PROFESSOR, GLOBAL HEALTH MANAGEMENT BUSINESS SCHOOL AND THE CENTER FOR GLOBAL HEALTH UCDENVER INTERNATIONAL HEALTH International health has been seen as
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease
REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Stalevo/Comtan in the 8MM Parkinson
Breath Analyzer Market Opportunities, Market Forecasts, and Market Strategies,
Breath Analyzer Market Opportunities, Market Forecasts, and Market Strategies, 2005-2011 Breath Analyzer Market Assessment Picture of fish breath by Susan Eustis WinterGreen Research, Inc. Lexington, Massachusetts
Study Design and Analysis in Late-Stage Cancer Immunotherapy Trials
Study Design and Analysis in Late-Stage Cancer Immunotherapy Trials EMA-CDDF Joint Meeting, London, UK Tai-Tsang Chen, PhD Executive Director Global Biometrics Sciences Bristol-Myers Squibb Disclosure
Watson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
Background Information
Background Information Erlangen, November 26, 2017 RSNA 2017 in Chicago: South Building, Hall A, Booth 1937 Artificial intelligence: Transforming data into knowledge for better care Inspired by neural
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease
Predictive Analytics and machine learning in clinical decision systems: simplified medical management decision making for health practitioners
Predictive Analytics and machine learning in clinical decision systems: simplified medical management decision making for health practitioners Mohamed Yassine, MD Vice President, Head of US Medical Affairs
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
Staying on top of the current research landscape with InCites Benchmarking & Analytics: An immuno-oncology case study
Staying on top of the current research landscape with InCites Benchmarking & Analytics: An immuno-oncology case study SLA Annual Conference Biomedical & Life Sciences Division Breakfast June 2017 Amy Braden,
Artificial Intelligence AI for Smarter Healthcare
Artificial Intelligence AI for Smarter Healthcare What is Artificial Intelligence? What is Artificial Intelligence? Artificial Intelligence is a way of making a computer, a computer-controlled robot,
Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
Pioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
Newsletter May, Recent advances in. Life Sciences
Newsletter May, 2018 Recent advances in Life Sciences VOLUME 1/ISSUE 2 WWW.MAXVAL.COM IN THIS ISSUE: 01 Base Editors in CRISPR This article presents a base editing approach to expand the scope and efficiency
Synribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
National Academies Next Generation SAMPLE Researchers TITLE Initiative HERE
National Academies Next Generation SAMPLE Researchers TITLE Initiative HERE Dennis A. Dean, II, PhD Sanofi Auditorium July 13, 2017 sevenbridges.com A little about me Research Experience Analytics and
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
Custom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
Consolidated Financial Results for the Third Quarter of Fiscal Year 2017
Consolidated Financial Results for the Third Quarter of Fiscal Year 2017 1. Revenue Revenue totaled 200.6 billion, which was an increase of 11.7 billion (6.2%) from the corresponding period of the previous
NHS Healthcare Science. Cumbria & NE LWAB. 4 th September 2018
NHS Healthcare Science Cumbria & NE LWAB 4 th September 2018 Executive Summary The Business Proton Partners International (PPI) will build, own and operate a network of Proton Beam Therapy Cancer Centres
A robust new approach. A rising trend
A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective. But with the increasing incidence
NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
The Role of Pharmaceutical Industry in Vaccine R&D
The Role of Pharmaceutical Industry in Vaccine R&D Jean-Paul Prieels 12/03/13 1 The Players : 5 majors share over 90% of the global vaccine market 2 new entrants : J&J (Crucell) and Takeda 12/03/13 2 Where
REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s
At the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Investment highlights Lead investigational product CAVATAK kills cancer cells with a bio-selected form of the common cold virus
PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
Personalized, Evidence-based, Outcome-driven Healthcare Empowered by IBM Cognitive Computing Technologies. Guotong Xie IBM Research - China
Personalized, Evidence-based, Outcome-driven Healthcare Empowered by IBM Cognitive Computing Technologies Guotong Xie IBM Research - China Explosion of Healthcare Data Exogenous data 1,100 Terabytes Generated
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
THE COST DRIVERS OF CANCER CARE
THE COST DRIVERS OF CANCER CARE Debra Patt, MD, MPH, MBA David Eagle, MD Ted Okon, MBA Don Sharpe 20156Community Oncology Alliance 1 Welcome & Introductions Debra Patt, MD, MPH, MBA Director of Public
Deep Learning Analytics for Predicting Prognosis of Acute Myeloid Leukemia with Cytogenetics, Age, and Mutations
Deep Learning Analytics for Predicting Prognosis of Acute Myeloid Leukemia with Cytogenetics, Age, and Mutations Andy Nguyen, M.D., M.S. Medical Director, Hematopathology, Hematology and Coagulation Laboratory,
Innovation from the Foundation Sonya Dumanis, PhD
Highlights in Research and Innovation from the Foundation Sonya Dumanis, PhD Senior Director of Innovation EPILEPSY FOUNDATION Our Mission: To lead the fight to overcome the challenges of living with epilepsy
INNOVATIONS IN BRAIN TUMOR MANAGEMENT
APRIL 5-6, 2019 NEW YORK Memorial Sloan Kettering Cancer Center presents INNOVATIONS IN BRAIN TUMOR MANAGEMENT Rockefeller Research Laboratories 430 East 67th Street New York, New York INNOVATIONS IN BRAIN
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
Exoskeleton : Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021
Exoskeleton : Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021 Economies of scale and new levels of patient progress for longer durations are provided by Exoskeletons. Exoskeleton target
Analysis of the U.S. Medical Computed Tomography Imaging Systems Market
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the U.S. Medical Computed Tomography Imaging Systems Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - Executive Summary Diabetic foot ulcers (DFUs) are a major complication of diabetes that occurs as a result of trauma to or
REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS Executive Summary Sales for Parkinson s Disease Market The Parkinson s disease market in the US,
HEALTHCARE AI DEVELOPMENT CYCLE
Dr. Keith Dreyer Chief Science Officer, ACR Data Science Institute ACR Board of Chancellors, Chairman Informatics Commission Chief Data Science Officer, MGH, BWH, Partners Healthcare Associate Professor
Why Making Connections
1 Why Making Connections The Internet Of Things In Healthcare January 14, 2016 Shafiq Rab, M.D., MPH Vice President, Chief Information Officer Hackensack University Medical Center About Hackensack University
First mover in making RNA sequencing clinically actionable in oncology
First mover in making sequencing clinically actionable in oncology Saving lives and making healthcare delivery more effective: by selecting the best drug for the patient, and the best patient for the drug
CancerBase R E S E A R C H
CancerBase R E S E A R C H CancerBase 1 WEB PRESENCE 4 ATOM HP 2 NCCN GUIDELINES 5 BIOINFORMATICS 3 CHOOSING DRUGS 6 MEDMIND Web Presence R E S E A R C H What is CancerBase trying to communicate? cancerbase.org
Attached from the following page is the press release made by BMS for your information.
September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September
London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. Professor Reza Razavi Centre Director
London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare Professor Reza Razavi Centre Director The traditional healthcare business model is changing Fee-for-service Fee-for-outcome
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major